Posts found in:
Healthcare & Life Science
KO Pharmacology Research and Drug Discovery Client Plato BioPharma, Inc. Acquired by Inotiv, Inc.
- KO Firm
- |
- October 26, 2021
KO Client Plato BioPharma, Inc., a Colorado-based pharmacology research and drug discovery company, has been acquired by leading contract research organization Inotiv, Inc. The KO team, led by partner John Gaddis, represented Plato BioPharma in the acquisition. Plato BioPharma specializes in cardiovascular, renal, pulmonary and hepatic therapeutic areas, specifically within…
KO Client Sydnexis Completes $45M Series B Financing
- KO Firm
- |
- August 25, 2021
Sydnexis, Inc., a clinical stage biopharmaceutical company, has completed a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund. The KO team, led by partners Kevin Gibson and Brad Schoenfeld, represented Sydnexis. The company sees progressive myopia (nearsightedness) in children as a “significant…
KO Client VitriVax Closes Series A Financing Round
- KO Firm
- |
- July 14, 2021
VitriVax, the developer of a novel stabilization and delivery platform for vaccines and therapeutics, has closed its first institutional financing round with Adjuvant Capital. KO partners Jon Taylor and Brad Schoenfeld, and attorney Matt Burns represented VitriVax in the financing round. The Series A proceeds will be used to develop…
Proactively Protecting Your Company’s Growth: The Early-Stage Guide to Using a Corporate Lawyer
- John W. Gaddis
- |
- June 21, 2021
When you have limited dollars for legal issues, it’s important to know where to spend those funds to maximize your company’s investment in legal resources without waste and inefficiency. Experienced corporate counsel will tell early stage companies in most industries to focus on two priorities as soon as possible: capital…
Addressing CRO Consolidation Risks: How to Protect Clinical Trials
- Ryan Ivey
- |
- May 18, 2021
Contract Research Organization (CRO) consolidation has become a constant force in the life sciences market. This shifting environment has made protecting clinical trial success and anticipating and planning for CRO consolidation risks critical for pharmaceutical and medical device companies when negotiating agreements. Working with high-performing CROs, with deep industry and…
KO Law Firm is Hiring Attorneys and Other Positions
- KO Firm
- |
- January 13, 2021
Koenig, Oelsner, Taylor, Schoenfeld & Gaddis PC (KO Law Firm) is growing. We are currently hiring for four positions: Contracts manager Paralegal Commercial attorney Life sciences attorney KO is an innovative corporate and commercial law firm with a team of experienced lawyers and a practical, efficient, business-focused approach. We have a…
Rethinking Supply Chain Agreements and Other Commercial Contracts to Manage Pandemic-Driven Uncertainty
- Brad L. Schoenfeld
- |
- January 11, 2021
Force majeure, supply chain agreements, commercial contracts and remote customer service — these are just a few of the many areas businesses are rethinking due to the COVID-19 pandemic. For life science companies, these areas take on significant and often urgent meaning as they apply to the pharmaceutical production and…
Closing M&A Deals in the “New Normal”
- Jennifer Rosenthal
- |
- September 29, 2020
Today, many have the misperception that M&A deals aren’t getting done because of the ongoing COVID-19 pandemic, or that the only deals closing are distressed deals that are unfavorable to the seller. But there’s more to the story. While we have seen a shift from a seller-favorable market to a…
